ストックスクリーナーアプリを入手
46.56
1.02%
-0.4556
前日終値:
$47.02
開ける：
$47.17
24時間の取引高:
474.09K
Relative Volume:
0.54
時価総額：
$2.73B
収益：
$45.48M
当期純損益:
$162.11M
株価収益率:
-17.37
EPS:
-2.68
ネットキャッシュフロー:
$-64.16M
1週間 パフォーマンス:
+4.37%
1か月 パフォーマンス:
+12.41%
6か月 パフォーマンス:
+60.59%
1年 パフォーマンス:
+159.99%
1日の値動き範囲:
$45.50
$48.00
1週間の範囲:
$43.96
$48.00
52週間の値動き範囲:
$13.72
$48.00
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
名前
Protagonist Therapeutics Inc
セクター
電話
(510) 474-0170
住所
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Buy |
| 2021-10-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-11 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-05-24 | 開始されました | Northland Capital | Outperform |
| 2021-01-06 | 開始されました | JP Morgan | Overweight |
| 2020-12-16 | 開始されました | Piper Sandler | Overweight |
| 2020-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-15 | 開始されました | Jefferies | Buy |
| 2020-05-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-05-09 | アップグレード | Stifel | Hold → Buy |
| 2018-12-06 | 開始されました | Nomura | Buy |
| 2018-01-29 | 開始されました | Stifel | Buy |
| 2017-07-21 | 開始されました | BTIG Research | Buy |
すべてを表示
Protagonist Therapeutics Inc (PTGX) 最新ニュース
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year High at $47.75 - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Sells $631,891.47 in Stock - Defense World
Principal Financial Group Inc. Sells 4,341 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist therapeutics CFO sells over $630k in company stock - Investing.com
HC Wainwright Increases Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $50.00 - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Sells $631,891.47 in Stock - MarketBeat
PTGX Shares Experience Surge in Value - Knox Daily
Protagonist Therapeutics director Waddill sells $360,000 in stock - Investing.com India
Protagonist Therapeutics director Waddill sells $360,000 in stock - Investing.com
Truist Securities Initiates Coverage of Protagonist Therapeutics (PTGX) with Buy Recommendation - MSN
HC Wainwright Boosts Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $50.00 - MarketBeat
TD Asset Management Inc Grows Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Bank of New York Mellon Corp - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of “Buy” from Analysts - Defense World
TD Asset Management Inc Boosts Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Protagonist Therapeutics Inc (PTGX) expanding its growth trajectory ahead - SETE News
Objective long/short (PTGX) Report - Stock Traders Daily
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines - AOL
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines - Yahoo Finance
Great Lakes Advisors LLC Decreases Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics stock hits 52-week high at $43.79 By Investing.com - Investing.com Australia
Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated by Analysts at Truist Financial - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High at $44.05 - MarketBeat
Protagonist Therapeutics stock hits 52-week high at $43.79 - Investing.com
Protagonist Therapeutics stock hits 52-week high at $43.79 By Investing.com - Investing.com Canada
Truist initiates coverage on Protagonist Therapeutics shares with Buy rating By Investing.com - Investing.com Canada
Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated at Truist Financial - MarketBeat
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - Simply Wall St
Candriam S.C.A. Sells 86,182 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Cannon Global Investment Management LLC Purchases New Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Check Out Protagonist Therapeutics Inc (PTGX)’s Trade Data Rather Than the Analysts’ Views - SETE News
Metric Analysis: Protagonist Therapeutics Inc (PTGX)’s Key Ratios in the Limelight - The Dwinnex
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 - StockTitan
Protagonist Therapeutics Inc [PTGX] Stock sold by Insider Waddill William D. for $0.32 million - Knox Daily
Protagonist Therapeutics stock hits 52-week high at $42.72 By Investing.com - Investing.com Australia
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year High at $43.31 - MarketBeat
Keeping an Eye on Protagonist Therapeutics Inc (PTGX) After Insider Trading Activity - Knox Daily
Protagonist Therapeutics stock hits 52-week high at $42.72 - Investing.com
Protagonist Therapeutics, Inc. announced that it expects to receive $18.04 million in funding. - Marketscreener.com
Protagonist Therapeutics, Inc. announced that it has received $18 million in funding from Pharmstandard International S.A., Johnson & Johnson InnovationJJDC, Inc., Lilly Ventures Management Company, LLC, Starfish Ventures Pty Ltd - Marketscreener.com
Taking the lead: Protagonist Therapeutics Inc (PTGX) - SETE News
SG Americas Securities LLC Buys Shares of 10,951 Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Hennion & Walsh Asset Management Inc. - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Protagonist Therapeutics : Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera - Marketscreener.com
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of “Buy” by Analysts - Defense World
Long Term Trading Analysis for (PTGX) - Stock Traders Daily
Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences - Marketscreener.com
Protagonist Therapeutics : to Present at the BMO 2019 Prescription for Success Healthcare Conference - Marketscreener.com
California State Teachers Retirement System Sells 3,153 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics Inc (PTGX) 財務データ
収益
当期純利益
現金流量
EPS
Protagonist Therapeutics Inc (PTGX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ali Asif | Chief Financial Officer |
Sep 11 '24 |
Sale |
44.49 |
14,203 |
631,872 |
34,960 |
| Waddill William D. | Director |
Sep 10 '24 |
Option Exercise |
12.88 |
8,000 |
103,040 |
20,000 |
| Waddill William D. | Director |
Sep 10 '24 |
Sale |
45.00 |
8,000 |
360,000 |
12,000 |
1.28%
1.94%
大文字化:
|
ボリューム (24 時間):